Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co Ltd is a Japanese pharmaceutical company that develops, manufactures, and markets ophthalmic products, including treatments for glaucoma, dry eye, and retinal diseases.
Business. Santen Pharmaceutical Co Ltd (4536.T) is a Japanese pharmaceutical company headquartered in Japan and primarily listed on the Tokyo Stock Exchange. The firm operates within the healthcare sector, specifically focusing on the research, development, and sale of pharmaceutical products. As detailed segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the global pharmaceuticals market. Its business model relies on product sales, with key performance indicators including pipeline depth, patent lifecycle management, and research and development efficiency.
Analyst recommendations
9 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Santen Pharmaceutical Co Ltd (4536.T) is a Japanese pharmaceutical company headquartered in Japan and primarily listed on the Tokyo Stock Exchange. The firm operates within the healthcare sector, specifically focusing on the research, development, and sale of pharmaceutical products. As detailed segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the global pharmaceuticals market. Its business model relies on product sales, with key performance indicators including pipeline depth, patent lifecycle management, and research and development efficiency.
Santen maintains a strong liquidity position with a current ratio of 2.58 and cash and equivalents of ¥92.997 billion, which provides a buffer against short-term obligations. The company's debt-to-equity ratio is 0.12, indicating a conservative capital structure with limited leverage. Free cash flow of ¥30.671 billion supports operational flexibility and potential reinvestment or shareholder returns.
Profitability metrics show Santen's return on equity (ROE) at 12.67% and return on assets (ROA) at 8.86%, both exceeding the typical thresholds for pharmaceutical firms, suggesting efficient use of equity and assets. Operating income of ¥46.163 billion and net income of ¥36.256 billion reflect strong earnings performance relative to its revenue base of ¥300.004 billion.
Geographically, Santen's revenue is primarily concentrated in Japan, with a significant portion derived from its domestic market. The company's exposure to international markets is limited, which may pose a risk in the event of domestic regulatory or economic shifts. Segment-wise, Santen's ophthalmic products dominate its revenue, with a focus on prescription drugs and specialty treatments.
Looking ahead, Santen's revenue is expected to grow modestly, supported by its strong product portfolio and market position in ophthalmology. The company's capital expenditure of ¥-11.019 billion indicates a focus on cost optimization rather than aggressive expansion. Analysts project a mean price target of ¥2,097.50, with a median of ¥2,075.00, reflecting a generally positive outlook.
Santen's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong cash reserves mitigate financial distress risks. However, the potential for dilution remains low, with no significant dilution sources identified in recent filings.
Recent events include the continued development of new ophthalmic treatments and the maintenance of a stable product pipeline. Santen has not disclosed any major regulatory or legal challenges in its recent filings, and its business operations remain largely unaffected by geopolitical factors.
- Santen maintains a conservative capital structure with a low debt-to-equity ratio of 0.12 and strong liquidity.
- The company's profitability metrics, including ROE of 12.67% and ROA of 8.86%, indicate efficient asset and equity utilization.
- Santen's revenue is heavily concentrated in Japan, which may expose it to domestic regulatory and economic risks.
- Analysts project a positive outlook with a mean price target of ¥2,097.50, suggesting confidence in the company's future performance.
- The company's low liquidity and dilution risks, along with strong cash reserves, provide a stable financial foundation.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 101,87 |
| Revenue | —no estimate | —no estimate | 289,2B JPY |
| Operating income | —no estimate | —no estimate | 55,0B JPY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Santen Pharmaceutical Co Ltd Market data — financials · 2026-05-26
- Santen Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26
- Santen Pharmaceutical Co Ltd Market data — ESG · 2026-05-26